Navamedic ASA
Kathrine Gamborg Andreassen is an experienced executive in the health and pharmaceutical industries, currently serving as CEO and Chair of the Board at Navamedic ASA since June 2018. Additionally, Kathrine holds board member positions at Observe Medical and is an industry expert at Infima. Previously, Kathrine founded and chaired Novicus Pharma AS, focusing on OTC and OTX products for the Nordic market, and led Weifa AS as CEO, developing a range of medicinal products and supplements. Further experience includes roles as VP of Consumer Health at Vistin Pharma AS and Group Marketing and Communications Director at Kemetyl Group. Educationally, Kathrine holds a Master of Science in business from the University of Wisconsin-Madison and a Bachelor of Business Administration in International Marketing from Handelsakademiet.
This person is not in any teams
Navamedic ASA
Navamedic is a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers. Our product portfolio consists of prescription and OTC pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like UK and Greece. Our headquarter is in Oslo, Norway and we are listed on the Oslo Stock Exchange (ticker: NAVA). We are about 30 highly qualified employees with strong competence in regulatory affairs, quality assurance, reimbursement, marketing and sales and thus a full-service provider securing market access through our local competence.